Robert V. Talanian

Abbott (United Kingdom)

Papers

1

Total Citations

11

H-Index

1

About

Robert V. Talanian is a structural biologist and drug discovery scientist whose work bridges the gap between protein engineering and therapeutic design. His primary research focuses on structure-based drug design, protein mutagenesis, and kinase biology, with a particular emphasis on understanding how rational modifications to protein structures can accelerate the development of targeted inhibitors. His most notable contribution, "Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study" (2009), demonstrates a systematic approach to engineering protein variants that facilitate crystallographic studies and inhibitor screening. This work has accumulated over 11 citations, reflecting its utility in the field of kinase-targeted drug discovery. Talanian's expertise lies in integrating molecular biology techniques with structural analysis to solve challenges in drug development, particularly for kinases involved in inflammatory and oncogenic signaling pathways. His research has provided practical frameworks for optimizing protein constructs to improve expression, stability, and crystallization—essential steps in the rational design of small-molecule therapeutics. Through his methodical approach, Talanian has contributed to advancing the efficiency of structure-guided drug discovery, making his work a valuable resource for researchers seeking to apply similar strategies to other therapeutic targets.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
11 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Abbott (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago